Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the pharmaceutical giant posted stronger-than-expected earnings and revenue despite another ...

Eli Lilly (NYSE:LLY) on Thursday reported its Q4 2024 results, exceeding Wall Street forecasts and indicating a more than twofold rise in revenue from its weight loss and obesity drugs Mounjaro and ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...